Expo Hub
Meeting the rising tide of chronic disease - Trend Talk
About this session
Responsible for 63% of all deaths, non-communicable diseases will cost the world $30 trillion by 2030. Not only did the pandemic delay care for chronic disease patients, but it brought about further democratization of testing. Patients with liver disease, kidney disease, diabetes and allergies are taking command of their health. Clinicians are looking for tools for risk assessment.
Learn how testing accuracy and accessibility can help unlock a lab’s ability to evaluate patients impacted by this growing epidemic.
1 / 0
Jérôme Boursier
Centre Hospitalier Universitaire Angers, France
Tara Papacek
1 / 0
Enhanced Liver Fibrosis (ELF™) Test
Assess the risk of NAFLD/NASH progression and liver-related events with a simple blood test.
Diagnostic testing for diabetes and diabetes-related conditions
Whether routine testing for glucose, HbA1c, and urinary albumin; esoteric tests for insulin, C-peptide, and cystatin C; lipid panel tests; or testing for diabetes-related conditions such as heart, kidney, or liver disease, Siemens Healthineers offers a comprehensive portfolio of tests across platforms.